Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) EBITDA (2018 - 2025)

Exagen (XGN) has disclosed EBITDA for 8 consecutive years, with -$5.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 47.06% year-over-year to -$5.0 million, compared with a TTM value of -$14.1 million through Dec 2025, down 3.18%, and an annual FY2025 reading of -$14.1 million, down 3.18% over the prior year.
  • EBITDA was -$5.0 million for Q4 2025 at Exagen, down from -$3.1 million in the prior quarter.
  • Across five years, EBITDA topped out at -$2.6 million in Q2 2024 and bottomed at -$14.5 million in Q4 2022.
  • Average EBITDA over 5 years is -$6.0 million, with a median of -$5.1 million recorded in 2023.
  • The sharpest move saw EBITDA crashed 144.93% in 2022, then skyrocketed 65.05% in 2023.
  • Year by year, EBITDA stood at -$6.3 million in 2021, then plummeted by 131.71% to -$14.5 million in 2022, then surged by 64.48% to -$5.1 million in 2023, then soared by 34.27% to -$3.4 million in 2024, then crashed by 47.06% to -$5.0 million in 2025.
  • Business Quant data shows EBITDA for XGN at -$5.0 million in Q4 2025, -$3.1 million in Q3 2025, and -$2.6 million in Q2 2025.